Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Valeo Pharma Inc T.VPH

Alternate Symbol(s):  T.VPH.DB | VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:VPH)

VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE

Canada NewsWire 10 days ago

VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS

Canada NewsWire March 22, 2024

VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS

Canada NewsWire March 14, 2024

VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire March 7, 2024

VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES

Canada NewsWire February 13, 2024

VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP

Canada NewsWire February 2, 2024

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023

Canada NewsWire January 29, 2024

VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST

Canada NewsWire January 22, 2024

VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES

Canada NewsWire November 20, 2023
View More News ››

Opinion & Analysis (TSX:VPH)

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

Nico Popp December 9, 2020

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

Stockhouse Editorial September 29, 2020

BioNTech, CureVac, or Valeo Pharma: who brings the highest return to shareholders?

Stockhouse Editorial September 23, 2020

BioNTech, CureVac, Valeo Pharma - Growth after capital injection

Stockhouse Editorial September 11, 2020

Desert Gold, dynaCERT, Valeo Pharma - good news and the right time

Stockhouse Editorial September 3, 2020

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Stockhouse Editorial September 2, 2020
View More Opinion ››

Bullboard Posts (TSX:VPH)

Fourth Quarter and year-end 2023 Webcast and Conference Call

Valeo will host a conference call to discuss its fourth quarter and year-end 2023 results and highlights on Tuesday January 30...
Betteryear2 - January 29, 2024

VALEO PHARMA REPORTS RECORD ANNUAL REVENUES

Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4...
Betteryear2 - January 29, 2024

VPH

Interesting opportunityi high revenue high expenses. See where this sits next spring could be a nice play here at these levels
Bluechips19 - November 22, 2023

UPDATE ON OPHTHALMOLOGY BUSINESS UNIT T.VPH

Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + Lomb SIMBRINZA®...
Betteryear2 - July 4, 2023

VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES

VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES - Valeo Pharma
NonoRobotSG - June 15, 2023

VPH: To profit from forest fires!

VPH sells products with a focus on Respiratory/Allergy.
Royal10 - June 6, 2023
View more Bullboard ››

Ucore Rare Metals Inc.

Ucore Rare Metals Inc.

Ucore is focused on rare and critical-metal resources, extraction, beneficiation, and separation technologies with the ...
View More »